Advanced Therapy Medicinal Products (ATMPs) — including cell and gene therapies, tissue-engineered products, and somatic cell therapies — represent the most innovative frontier in modern medicine. The Netherlands plays an increasingly important role in the global ATMP market, with centers of excellence in Amsterdam, Leiden, and Utrecht.
What Are ATMPs and Why Are They So Complex?
ATMPs are medicines based on genes, cells, or tissue. They offer groundbreaking treatment options for serious and rare conditions, including certain types of cancer, hereditary genetic diseases, and degenerative disorders. However, the complexity of ATMPs is considerably greater than that of classical pharmaceutical products. Manufacturing ATMPs requires specialized GMP facilities for cell culture and gene modification, robust quality assurance in line with EMA guidelines for ATMPs, regulatory expertise for Marketing Authorization or Hospital Exemption applications, specialized supply chain management given the often short shelf life of living cell material, and clinical expertise to guide phase I/II/III trials.
The Role of SIRE Life Sciences in the ATMP Sector
SIRE Life Sciences has a network of specialized consultants with ATMP expertise in the Netherlands and across Europe. Whether it involves recruiting a Process Development Scientist for cell therapy, a Regulatory Affairs Manager for EMA submissions of ATMP dossiers, a QA specialist for ATMP GMP compliance, or a clinical project manager for ATMP Phase II trials, SIRE Life Sciences connects your organization with the scarce talent in this field.
The Netherlands as an ATMP Hub
With Sanquin, Amsterdam UMC, Leiden UMC, Pivot Park Nijmegen, and dozens of biotech companies in the Amsterdam and Leiden regions, the Netherlands has grown into an important ATMP hub in Europe. Demand for specialized professionals in this field is growing strongly, while the supply of experienced ATMP specialists remains limited.
This article originally appeared on the SIRE Life Sciences blog.
Top comments (0)